TJP1 and colitis: Group M and H showed a significantly decreased content of pro-inflammatory cytokines IL-1β, IL-6, IL-8 and TNF-α, significantly increased content of IL-4 and IL-10, alleviated colitis symptoms, increased expression levels of tight junction proteins ZO-1, Occludin and Claudin-1, and protected intestinal mucosal barrier.